Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer
CTR20191444Phase 3Active
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of talazoparib, enzalutamide in prostate cancer (PCa), sponsored by Pfizer. Started Apr 2020; status: active.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20191444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191444.